Unofficial reports suggested that individuals in Tanzania were exhibiting Ebola-like symptoms, but the WHO reports not receiving detailed information from the country.
Four pharma companies are providing half of the investment required for ‘world’s largest genetics project’, in return for access to the genomic data generated.
Lonza’s facility in Singapore will provide Celltrion with the drug substance product to meet demand for the latter’s Remsima biosimilar in the European and US market.
Once a neglected area of pharma research, companies are now investing heavily after several major commercial successes and with promising new avenues of research progressing.
The US HSS will provide funding to Merck for a year’s supply of its investigational Ebola vaccine for use in DR Congo to combat the repeated outbreaks of the virus.
J&J will test a vaccine candidate for HIV prevention in 3,800 men across the US and Europe, at the same time as ViiV releases positive comparative data on its HIV treatment.
Fuji Pharma signs agreement to receive an exclusive supply of the ustekinumab biosimilar for the Japanese market, furthering a previous investment agreement.
Pfizer has launched the first biosimilar to J&J’s Procrit and Amgen’s Epogen in the US at a ‘significant discount’ to competitors’ wholesale acquisition costs.
A US district court has denied Johnson & Johnson’s motion to dismiss Pfizer’s Inflectra lawsuit, a case claiming anticompetitive practices blocked US uptake of the Remicade biosimilar.
Eusa Pharma has completed the acquisition of global rights for J&J’s Sylvant, shortly after selling its critical care business to Serb Pharmaceuticals.
